In particular, our in vivo and in vitro experiments showed that fasting could dramatically elevate the expression of the cholesterogenic gene FDFT1. Moreover, we showed that FDFT1 played an important tumor-suppressive role with clinical significance and function in CRC, and was also an important downstream target of fasting. This evidence concerns the gene FDFT1 and colorectal carcinoma.